Lignamed, LLC

Aum Biotech, LLC is a cutting-edge biotechnology company based in Philadelphia, PA, specializing in RNA silencing products for cellular and animal studies. Their innovative FANA technology offers a single-step guaranteed knockdown without the need for transfection reagents, making it ideal for a wide range of applications. With a focus on mRNA knockdown, miRNA inhibition, lncRNA knockdown, and viral RNA knockdown, Aum Biotech's AUMsilence, AUMantagomir, AUMlnc, and AUMsilence V products provide efficient and reliable solutions for translation blocking. Backed by a range of publications, testimonials, and protocols, Aum Biotech is at the forefront of RNA silencing research and development.Generated from the website

VestedIn, formerly known as the West Philadelphia Financial Services Institution, is a community development financial institution dedicated to providing capital, grants, and technical assistance to small businesses and entrepreneurs across seven counties in Pennsylvania, New Jersey, and Delaware. With a mission to break the cycles of poverty and build generational wealth, VestedIn champions economic growth and empowerment within the community. Through various programs, including the Wes Gold Fellows youth development initiative and the BSmart entrepreneurship program, VestedIn equips individuals with the skills and resources necessary for success. Since its inception, the organization has facilitated significant financial support, creating jobs and enhancing the vitality of local businesses. Generated from the website

Mebias Discovery is a Philadelphia-based company specializing in innovative drug discovery and development, with a focus on G Protein Coupled Receptors (GPCRs). Their proprietary membrane protein-NMR drug discovery platform enables the identification of highly selective molecules that bind to GPCR targets, eliminating adverse effects and maximizing therapeutic potential. With seven years of experience, Mebias Discovery has successfully validated their unique drug discovery platform and identified an FDA-approved Investigational New Drug for the mu-opioid receptor. Additionally, they are currently developing Sphingosine 1-phosphate receptor agonists for the treatment of neuropathic pain.Generated from the website